Sophia Abene

Mary Rochelle Smith, MD, Julie J Lee, MD, and Amy Chang, MD, PharmD, share expert strategies for implementing effective clinical decision support tools in practice.

Study shows 2′-fucosyllactose, a sugar in human milk, could reduce norovirus replication, offering hope for new treatments amid rising cases.

Patrick D Crowley, DO explains the impact of the "skip phenomenon" in Staphylococcus lugdunensis infective endocarditis, linking it to longer hospital stays and higher mortality rates.

A new treatment of albendazole and ivermectin shows higher efficacy against Trichuris trichiura and hookworm infections, offering a new treatment approach for soil-transmitted worms.

Babafela Awosile, DVM, MVSc, PhD, DACVPM, discusses the need for surveillance as blaCTX-M-15 and blaCMY-2 spread in humans, animals, and the environment.

The Phase 1 clinical trial for ARCT-2304, a self-amplifying mRNA vaccine, seeks to address pandemic influenza risk as H5N1 cases increase.

How targeting zinc deprivation in VIM-2-expressing bacteria may open new doors for treating multidrug-resistant infections, with azithromycin showing promise.

Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.

This week, norovirus cases linked to contaminated oysters, while the first US death from H5N1 avian influenza is confirmed, the FDA updates RSV vaccine labeling due to Guillain-Barré Syndrome risks, and more.

CEO Larry Sutton, MD, PhD, discusses SIDIPREV, a novel oxygen-based therapy aimed at preventing C difficile infections.

New findings explore how HSV-1 infection influences tau phosphorylation via the cGAS-STING-TBK1 pathway, offering potential therapeutic avenues for Alzheimer's treatment.

Study reveals how bacteria secrete natural products that make their competitors vulnerable to viral infection, with potential implications for enhancing phage therapy and shaping microbial ecosystems.

The updated recommendations simplify vaccine eligibility while addressing both cost-effectiveness and racial health disparities.

CEO Larry D Sutton, MD, PhD, elaborates on the company's strategy and the science behind SIDIPREV to prevent C difficile infections in hospitalized patients.

Rising temperatures and changing humidity are undermining natural pest control, putting North American forests at risk.

Nationwide norovirus cases have recently increased, followed by an FDA warning for consumers to avoid oysters contaminated in a recent outbreak.

The Louisiana Department of Health announced the news late yesterday, and it is the first death in the US associated with the H5N1 virus.

A case series of 13 patients suggests that extended courses of Paxlovid could benefit some Long COVID patients, but the results are inconsistent.

Recent study highlights Paxlovid’s ability to reduce hospitalizations and mortality in high-risk populations, but underscores the need for personalized treatment.

This week, the CDC MMWR highlights a major blastomycosis outbreak and increased tularemia cases, CHOP's feedback reports improve antibiotic stewardship in pediatric pneumonia, and more.

New recommendations emphasize shorter, all-oral regimens for both drug-susceptible and drug-resistant TB.

Systematic reviews and localized studies reveal rising resistance rates in pediatric H pylori infections, highlighting the need for improved diagnostics and treatment approaches.

The largest blastomycosis outbreak linked to a paper mill in Michigan and a 56% increase in tularemia cases over the past decade.

Exploring the challenges and strategies for combating MDR Pseudomonas aeruginosa infections, as discussed with Jason Pogue, PharmD, BCPS, BCIDP

Charlotte Allerton explains how ibuzatrelvir, a second-generation treatment, could reduce drug interactions and taste disturbances compared to PAXLOVID, offering a simplified approach for high-risk patients.

Jason M Pogue, PharmD, BCPS, BCIDP discussed ceftolozane tazobactam’s effectiveness over ceftazidime avibactam, particularly in pneumonia patients, where it reduced the likelihood of recurrent infections.

6.4% of US adults experience Long COVID, with 19.8% reporting significant activity limitations, while the updated RECOVER study refines the classification index.

This week, recent studies show progress in healthcare, including an mRNA vaccine for C difficile, the rise of antimicrobial resistance, peer-assisted telemedicine for hepatitis C in rural areas, and more.

Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.

Study shows this could reduce hepatitis C and injection-related infections, with each dollar invested saving $2 in treatment costs.